Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1999-02-01
2000-04-25
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514170, A61K 3156
Patent
active
060544473
ABSTRACT:
The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.
REFERENCES:
patent: 5543150 (1996-08-01), Bologna et al.
Sarrell, Phillip M., "How Progestins Compromise the Cardioprotective Effects of Estrogen," Menopause: The Journal of the North American Menopause Society, vol. 2, No. 4, 1995, pp. 187-190.
Sullivan, Jay M. et al., "Progestin Enhances Vasconstrictor Responses in Postmenopausal Women Receiving Estrogen Replacement Therapy," Menopause: The Journal of the North American Menopause Society, vol. 2, No. 4, 1995, pp. 193-199.
Williams, J. Koudy et al., "Effects of Hormone Replacement Therapy on Reactivity of Atherosclerotic Coronary Arteries in Cynomolgus Monkeys," Journal of the American College of Cardiology, vol. 24, No. 7, Dec. 1994, pp. 1757-1761.
Perrot-Applanat, M. et al., "Progesterone Receptor Expression in Human Saphenous Veins," Circulation, vol. 92, No. 10, Nov. 15, 1995, pp. 2975-2983.
Stumpf, W.E., Steroid hormones and the cardiovascular system: Direct actions of estradiol, progesterone, testosterone, gluco- and mineralcorticoids, and soltriol [vitamin D] on central nervous regulatory and peripheral tissues, Experimentia, vol. 46, No. 1, Jan. 15, 1990, pp. 13-25.
Ingegno, Michael D. et al., "Progesterone Receptors in the Human Heart and Great Vessels," Laboratory Investigation, vol. 59, No. 3, Sep. 1988, pp. 353-356.
Perrot-Applanat, M. et al., "Immunocytochemical Demonstration of Estrogen and Progesterone Receptors in Muscle Cells of Uterine Arteries in Rabbits and Humans," Endocrinology, vol. 123, No. 3, Sep. 1988, pp. 1511-1519.
Brucket, Eric et al., "Estrogens and Progestins in Postmenopausal Woman: Influence on Lipid Parameters and Cardiovascular Risk," Hormone Research, vol. 43, pp. 100-103.
Sullivan, Jay M. et al., "Considerations for contraception in women with cardiovascular disorders," American Journal of Obstetrics and Gynecology, vol. 168, No. 6, Part 2, Jun. 1993, pp. 2006-2011.
Sammour, M.B. et al., "Progesterone Therapy in Pregnancy Induced Hypertension-Therapeutic Value and Hormonal Profile," Clinical and Experimental Hypertension: Part B, Hypertension in Pregnancy, vol. B1, No. 4, 1982, pp. 455-478.
Castelo-Branco, Camil et al., "Postmenopausal Hormone Replacement Therapy with Low-Dose Medroxyprogesterone Acetate," The Journal of Reproductive Medicine, vol. 40, No. 4, Apr. 1995, pp. 305-311.
Kafonek, Stephanie D., "Postmenopausal Hormone Replacement Therapy and Cardiovascular Risk Reduction," Drugs Supplement: Treatment of Lipoprotein Disorders in Women, vol. 47, Supplement 2, 1994, pp. 16-24.
Giraud, George D. et al., "Effects of estrogen and progestin on aortic size and compliance in postmenopausal women," American Journal of Obstetrics and Gynecology, vol. 174, No. 6, Jun. 1996, pp. 1708-1718.
Barberis, Massimo C.P. et al., "Immunocytochemical Detection of Progesterone Receptors," Chest, vol. 107, No. 3, Mar. 1995, pp. 869-872.
Gaspard, U. et al., "Impact Metabolique des Oestroprogestatifs Actuels et Repercussions Cardiovaculaires," Bulletin et Memoires de l'Academie Royale de Medecine de Belgique, vol. 146, Nos. 8-10, 1991, pp. 334-342, at English summary on p. 341.
Horwitz, Kathryn B. et al., "Canine Vascular Tissues are Targets for Androgens, Estrogens, Progestins and Glucocorticords," The Journal of Clinical Investigation, vol. 69, Apr. 1982, pp. 750-758.
Gambrell, Jr., R.. Don, "Use of Progestogens in Postmenopausal Woman," International Journal of Fertility, vol. 34, No. 5, Sep./Oct. 1989, pp. 315-321.
Abstract, Section CH, Week 8523, Derwent Publications Ltd., London, GB; AN 85-139803 XP002055336 & SU 1 124 906 (Ivan Medicine Inst.), Nov. 23, 1984.
Giuseppe, Rosano et al., Medroxyprogesterone but not natural progesterone reverses the beneficial effect of estradiol 17 beta upon exercise-induced myocardial ischemia, Circulation (Supplement), vol. 94, No. 8 p. 18 (Oct. 15, 1996).
Rosano et al. Maturitas 27 (Suppl.), Nov. 3-7, 1996.
Jiang et al, Eu. J. Pharmacol:, vol. 211, pp. 163-167, 1992.
Fahraeus et al, Eu. J. Clinical Investig, vol. 13, pp. 447-453, 1983.
Omar et al, J. Clinical Endocrin. and Metab., vol. 80(2), pp. 370-373, 1995.
Belfort et al, Am. J. Obstet. Gynecol. vol. 174(1) Part 1, pp. 246-253, Jan. 1996.
Bologna William J.
Levine Howard L.
Columbia Laboratories, Inc.
Cook Rebecca
LandOfFree
Progesterone for treating or reducing ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Progesterone for treating or reducing ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Progesterone for treating or reducing ischemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993504